Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1995 Apr;86(4):406–413. doi: 10.1111/j.1349-7006.1995.tb03071.x

Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin

Shinzoh Kudoh 1, Masahiro Fukuoka 2, Noriyuki Masuda 1, Atsuko Yoshikawa 1, Yoko Kusunoki 1, Kaoru Matsui 1, Shun‐ichi Negoro 2, Nobuhide Takifuji 2, Kazuhiko Nakagawa 1, Tomonori Hirashima 1, Takashi Yana 1, Minoru Takada 1,✉
PMCID: PMC5920836  PMID: 7775263

Abstract

Two phase I trials of irinotecan (CPT‐11) in combination with cisplatin were conducted. In both cases, the dose‐limiting toxicities were leukopenia and/or diarrhea. During these trials the pharmacokinetics of CPT‐11 and its active metabolite, 7‐ethyl‐10‐hydroxycamptothecin (SN‐38), were investigated to evaluate the relationship between pharmacokinetic parameters and diarrhea, since this is an unpredictable and severe toxicity of combination chemotherapy using CPT‐11 and cisplatin. Twenty‐three previously untreated patients with advanced lung cancer were evaluated in the pharmacokinetic study. Ten patients received CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 60 mg/m2. The other 13 patients received CPT‐11 at 80 or 90 mg/m2 plus cisplatin at 80 mg/m2 with the granulocyte colony‐stimulating factor support (2 μg/kg × 16 days). CPT‐11 was given as a 90‐min intravenous infusion on days 1, 8, and 15. Cisplatin was given on day 1. The pharmacokinetics of CPT‐11 and SN‐38 were analyzed on day 8 during the first course of treatment. The maximum tolerated dose of CPT‐11 was 90 mg/m2 in both phase I trials. The severity of diarrhea was best correlated with the peak plasma concentration of SN‐38 among the pharmacokinetic parameters tested. In addition, patients with a plasma SN‐38 level > 12.4 ng/ml at 1.75 h after the start of CPT‐11 infusion had a higher incidence of Eastern Cooperative Oncology Group grade 3–4 diarrhea than those with a lower SN‐38 level (P=0.0003). Stepwise logistic regression analysis identified the SN‐38 concentration as a significant contributor to the development of diarrhea (P=0.0021). We conclude that there is a clear relationship between the SN‐38 concentration and diarrhea during chemotherapy with CPT‐11 plus cisplatin.

Keywords: CPT‐11, Pharmacokinetics, Diarrhea

Full Text

The Full Text of this article is available as a PDF (417.2 KB).

REFERENCES

  • 1).Kaneda , N. , Nagata , H. , Furuta , T. and Yokokura , T.Metabolism and pharmacokinetics of the camptothecin analogue CPT‐11 in the mouse . Cancer Res. , 50 , 1715 – 1720 ( 1990. ). [PubMed] [Google Scholar]
  • 2).Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino] carbonyloxycamptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 3).Gallo , R. , Whang‐Peng , J. and Adamson , R.Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin . J. Natl. Cancer Inst. , 46 , 789 – 795 ( 1971. ). [PubMed] [Google Scholar]
  • 4).Gellert , M.DNA topoisomerases . Annu. Rev. Biochem. , 50 , 879 – 910 ( 1981. ). [DOI] [PubMed] [Google Scholar]
  • 5).Hsiang , Y.‐H. , Hertzberg , R. , Hecht , S. and Liu , L. F.Camptothecin induces protein‐linked DNA breaks via mammalian DNA topoisomerase I . J. Biol. Chem. , 260 , 14873 – 14878 ( 1985. ). [PubMed] [Google Scholar]
  • 6).Hsiang , Y.‐H. and Liu , L. F.Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin . Cancer Res. , 48 , 1722 – 1726 ( 1988. ). [PubMed] [Google Scholar]
  • 7).Liu , L. F.DNA topoisomerase poisons as antitumor drugs . Annu. Rev. Biochem. , 58 , 351 – 375 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 8).Tsuruo , T. , Matsuzaki , T. , Matsushita , M. , Saito , H. and Yokokura , T.Antitumor effect of CPT‐11, a new derivative of camptothecin, against pleiotropic drug‐resistant tumors in vitro and in vivo . Cancer Chemother. Pharmacol. , 21 , 71 – 74 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 9).Taguchi , T. , Wakui , A. , Hasegawa , K. , Niitani , H. , Furue , H. , Ohta , K. and Hattori , T.Phase I clinical study of CPT‐11 . Jpn. J. Cancer Chemother. , 17 , 115 – 120 ( 1990. ) ( in Japanese ). [PubMed] [Google Scholar]
  • 10).Gandia , D. , Armand , J. , Chabot , G. , Abigerges , D. , Rougier , P. , Ruffie , P. , Cote , C. and Mathieu‐Boue , A.Phase I study of the new camptothecin analogue CPT‐11 administered every 3 weeks . Proc. Am. Assoc. Cancer Res. , 33 , 260 ( 1992. ). [Google Scholar]
  • 11).Negoro , S. , Fukuoka , M. , Masuda , N. , Takada , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Niitani , H. and Taguchi , T.Phase I study of weekly intravenous infusions of CPT‐11, a new derivative of camptothecin, in the treatment of advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 83 , 1164 – 1168 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 12).Rothenberg , M. , Kuhn , J. , BurrisIII , H. , Nelson , J. , Eckardt , J. , Tristan‐Marales , M. , Hilsenbeck , S. , Weiss , G. , Smith , L. , Rodriguez , G. , Rock , M. and Von Hoff , D.Phase I and pharmacokinetic trial of weekly CPT‐11 . J. Clin. Oncol. , 11 , 2194 – 2204 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 13).Rowinsky , E. K. , Grochow , L. B. , Ettinger , D. S. , Sartorius , S. E. , Lubejko , B. G. , Chen , T.‐L. , Hendricks , C. , Rock , M. K. and Donehower , R. C.Phase I and pharmacological study of novel topoisomerase I inhibitor 7‐ethyl‐10‐[4‐(1‐piperidino)‐1‐piperidino] carbonyloxycamptothecin (CPT‐11) administered as a ninety‐minute infusion every 3 weeks . Cancer Res. , 54 , 427 – 436 ( 1994. ). [PubMed] [Google Scholar]
  • 14).Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 15).Masuda , N. , Fukuoka , M. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Kudoh , S. , Negoro , S. , Nishioka , M. , Nakagawa , K. and Takada , M.CPT‐11: a new derivative of camptothecin for the treatment of refractory or relapsed small‐cell lung cancer . J. Clin. Oncol. , 10 , 1225 – 1229 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 16).Negoro , S. , Fukuoka , M. , Niitani , H. and Taguchi , T.Phase II study of CPT‐11, new camptothecin derivative, in small cell lung cancer (SCLC) . Proc. Am. Soc. Clin. Oncol. , 10 , 241 ( 1991. ). [Google Scholar]
  • 17).Takeuchi , S. , Noda , K. , Yakushiji , M.and the CPT‐11 Study Group on Gynecologic Malignancy. Late phase II study of CPT‐11, topoisomerase I inhibitor, in advanced cervical carcinoma (CC) . Proc. Am. Soc. Clin. Oncol. , 11 , 224 ( 1992. ). [Google Scholar]
  • 18).Takeuchi , S. , Dobashi , K. , Noda , K. , Yakushiji , M. , Taguchi , T.and the CPT‐11 Study Group on Gynecologic Malignancy. A late phase II study of CPT‐11 on uterine cervical cancer and ovarian cancer . Jpn. J. Cancer Chemother. , 18 , 1681 – 1689 ( 1991. ) ( in Japanese ). [PubMed] [Google Scholar]
  • 19).Shimada , Y. , Yoshino , M. , Wakui , A. , Nakao , I. , Futatsuki , K. , Sakata , Y. , Kambe , M. and Taguchi , T.Phase II study of CPT‐11, a new camptothecin derivative, in metastatic colorectal cancer . J. Clin. Oncol. , 11 , 909 – 913 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 20).Ohno , R. , Okada , K. , Masaoka , T. , Kuramoto , A. , Arima , T. , Yoshida , Y. , Ariyoshi , H. , Ichimaru , M. , Sakai , Y. , Oguro , M. , Ito , Y. , Morishima , Y. , Yokomaku , S. and Ota , K.An early phase II study of CPT‐11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma . J. Clin. Oncol. , 8 , 1907 – 1912 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 21).Kudoh , S. , Takada , M. , Masuda , N. , Nakagawa , K. , Itoh , K. , Kusunoki , Y. , Negoro , S. , Matsui , K. , Takifuji , N. , Morino , H. and Fukuoka , M.Enhanced antitumor efficacy of a combination of CPT‐11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts . Jpn. J. Cancer Res. , 84 , 203 – 207 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22).Takada , M. , Fukuoka , M. , Kudoh , S. , Masuda , N. , Nakagawa , K. , and Kishimoto , S.Synergistic effects of CPT‐11 and cisplatin or etoposide on human lung cancer cell lines and xenografts in nude mice . Proc. Am. Assoc. Cancer Res. , 33 , 226 ( 1992. ). [Google Scholar]
  • 23).Masuda , N. , Fukuoka , M. , Takada , M. , Kusunoki , Y. , Negoro , S. , Matsui , K. , Kudoh , S. , Takifuji , N. , Nakagawa , K. and Kishimoto , S.CPT‐11 in combination with cisplatin for advanced non‐small‐cell lung cancer . J. Clin. Oncol. , 10 , 1775 – 1780 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 24).Masuda , N. , Fukuoka , M. , Kudoh , S. , Matsui , K. , Kusunoki , Y. , Nakagawa , K. , Hirashima , T. , Tamanoi , M. , Nitta , T. , Yana , H. , Negoro , S. , Takifuji , N. and Takada , M.Phase I study of irinotecan and cisplatin with granulocyte colony‐stimulating factor support for advanced non‐small cell lung cancer . J. Clin. Oncol. , 12 , 90 – 96 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 25).Masuda , N. , Fukuoka , M. , Kudoh , S. , Kusunoki , Y. , Matsui , K. , Takifuji , N. , Nakagawa , K. , Tamanoi , M. , Nitta , T. , Hirashima , T. , Negoro , S. and Takada , M.Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer . Br. J. Cancer , 68 , 777 – 782 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26).Ohe , Y. , Sasaki , Y. , Shinkai , T. , Eguchi , K. , Tamura , T. , Kojima , A. , Kunikane , H. , Okamoto , H. , Karato , A. , Kanzawa , F. and Saijo , N.Phase I study and pharmacokinetics of CPT‐11 with 5‐day continuous infusion . J. Natl. Cancer Inst. , 84 , 972 – 974 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 27).Sasaki , Y. , Morita , M. , Miya , T. , Shinkai , T. , Eguchi , K. , Tamura , T. , Ohe , Y. and Saijo , N.Pharmacokinetic (PK) and pharmacodynamic (PD) analysis of CPT‐11 and its active metabolite SN‐38 . Proc. Am. Soc. Clin. Oncol. , 11 , 111 ( 1992. ). [Google Scholar]
  • 28).Slichenmyer , W. J. , Rowinsky , E. K. , Donehower , R. C. and Kaufmann , S. H.The current status of camptothecin analogues as antitumor agents . J. Natl. Cancer Inst. , 85 , 271 – 291 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 29).Tsuji , T. , Kaneda , N. , Kado , K. , Yokokura , T. , Yoshimoto , T. and Tsuru , D.CPT‐11 converting enzyme from rat serum: purification and some properties . J. Pharmacobio-Dyn. , 14 , 341 – 349 ( 1991. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES